Singapore-based information science and healthcare expertise firm Holmusk introduced a collaboration with the Healthcare enterprise sector of German pharma and life sciences large Merck to assist sufferers and physicians in Asia-Pacific with a holistic therapy strategy for prediabetes and diabetes.
The partnership entails Holmusk’s GlycoLeap, a cell digital therapeutics platform that makes use of a extremely data-driven strategy to ship personalised dietary suggestions, interactive instructional classes, and 1-1 steerage with a professional well being coach. The objective is to assist sufferers obtain weight reduction and improved blood glucose management.
Digital well being options like GlycoLeap have the potential to trace, personalize and affect affected person behaviors in an efficient, partaking and scalable approach. By linking sufferers with a private well being coach, GlycoLeap will complement medicines for diabetes and prediabetes and contribute to diabetes prevention and enhancing power illness outcomes.
Starting with China, Malaysia and Hong Kong, sufferers with diabetes and/or prediabetes, relying on the Advertising and marketing Authorization in every nation, will have the ability to get entry to GlycoLeap via their docs later this yr.
THE LARGER TREND
Earlier in August this yr, life insurance coverage group AIA fashioned an unique APAC partnership with Holmusk to offer AIA’s shoppers with a wider vary of well being teaching instruments and options, leveraging the startup’s data-driven strategy to well being administration, MobiHealthNews reported. Holmusk additionally introduced a $21.5 million funding round, led by Optum Ventures (OV) and Well being Catalyst Capital (HCC) and included current buyers Heritas Capital and different people in Might 2020.
In December 2019, Merck signed a strategic collaboration with China’s one-stop healthcare ecosystem platform Ping An Good Doctor to collectively discover built-in options to advance clever healthcare in China.
Again in 2018, Merck also collaborated with Healthy Interactions, a inhabitants well being firm that gives each digital and in-person packages for power illness administration and training to launch a diabetes administration and engagement platform designed to assist in-person counseling packages.
ON THE RECORD
“This is a crucial step in the suitable path to offer sufferers in Asia-Pacific with a culturally-tailored digital device for holistic care. We have by no means been extra excited to work with Merck, who’s absolutely aligned with our imaginative and prescient to enhance affected person outcomes and pioneer beyond-the-pill options for its sufferers,” mentioned Dr Yau Teng Yan, Chief of Digital Therapeutics at Holmusk.
Dr Ulrike Hostalek, Govt Medical Director and Head of GMA Common Medication and Endocrinology on the Healthcare enterprise sector of Merck, mentioned: “Increasing the therapeutic providing past the treatment is a key pillar of how we envisage to assist sufferers and contribute to higher therapy outcomes. Way of life intervention performs a crucial position in controlling Impaired Fasting Glucose.
With Holmusk we’re glad to have discovered a accomplice who is ready to ship an evidence-based and scalable program to related sufferers throughout South East Asia, a area extremely impacted by Prediabetes. We’re additionally more than happy to additional develop our partnership with Holmusk after their profitable participation on the “Merck 350 analysis problem – Altering the world of Prediabetes” in 2018.”